Blis pushes commercialisation of cure

The company, which last week confirmed it will seek a main board listing, has also announced plans to raise up to $7 million from institutions to fund commercial development of the protein.

The protein, called Salivaricin B, is believed to prevent or control streptococcal throat infections. Blis is hoping to introduce the product into the market in tablet form within six months.

Last week Blis signed a contract with the University of Otago to buy the collection of several thousand other BLIS producing organisms. BLIS stands for Bacteriocin Like Inhibitory Substances.

"The acquisition is a terrific development for the company and the University because there is potential for many more discoveries and developments similar to Salivaricin B ", says Blis spokesman, David Parker.

In return for the organisms the university will acquire 20% of the issued capital of Blis Technologies following the institutional capital raising, while Blis will become the sole owner of the patent for Salivaricin B.

The company says the commercialisation of Salivaricin B will be aided by a joint venture between Blis and Zenith Technology, a bio-tech company with offices in Dunedin and Auckland.

Comments from our readers

No comments yet

Add your comment:

Your name:
Your email:	Not displayed to the public
Comment:
Comments to Sharechat go through an approval process. Comments which are defamatory, abusive or in some way deemed inappropriate will not be approved. It is allowable to use some form of non-de-plume for your name, however we recommend real email addresses are used. Comments from free email addresses such as Gmail, Yahoo, Hotmail, etc may not be approved.

Anti-spam verification:

Type the text you see in the image into the field below. You are asked to do this in order to verify that this enquiry is not being performed by an automated process.